Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd).

Ja Min ByunSung-Soo YoonYoungil KohChang-Ki MinJae Hoon LeeJaemin JoHyunkyung ParkJiyun LeeKa-Won KangYoojin Leenull null

Published in: Therapeutic advances in hematology (2020)

In conclusion, even with the advent of novel agents, HSCT still remains a valuable treatment modality with additive efficacy.

Keyphrases